Pilot study of dornase alfa (Pulmozyme) therapy for acquired ventilator ‐associated infection in preterm infants

ConclusionTreatment with dornase alfa is safe and treated infants had some improvement in FiO2 requirement but no improvement in MAP. A larger randomized trial is needed to evaluate the efficacy of this therapy. Pediatr Pulmonol. 2016; 9999:XX–XX. © 2016 Wiley Periodicals, Inc.

Source: Pediatric Pulmonology - January 2, 2017 Category: Respiratory Medicine Authors: Melissa Scala, Deborah Hoy, Maria Bautista, Judith Jones Palafoutas, Kabir Abubakar Tags: Original Article: Neonatal Lung Disease Source Type: research